<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03486626</url>
  </required_header>
  <id_info>
    <org_study_id>Ain ShamsMH</org_study_id>
    <nct_id>NCT03486626</nct_id>
  </id_info>
  <brief_title>Endometrial Thickness and Subendometrial Vascularity in Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin</brief_title>
  <official_title>Endometrial Thickness And Subendometrial Vascularity In Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The participants will receive metformin 500mg 3times per day for 3months and one month is
      left for spontaneous pregnancy to occur or not (primary outcome ) and the investigators will
      check endometrial thickness and subendometerial vascularity as markers of endometrial
      receptivity before and after the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy</measure>
    <time_frame>4 months</time_frame>
    <description>polycystic ovarian syndrome patients getting pregnant on receiving Metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness and Sub Endometrial vascularity</measure>
    <time_frame>4 months</time_frame>
    <description>Endometrial thickness and Sub Endometrial vascularity before and after receiving Metformin as markers of endometrial receptivity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Anovulatory</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin to increase pregnancy rate in polycystic ovarian syndrome patients</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCO syndrome patients have the following criteria:

        Age of the patient between 20 - 40 years old. All subjects are not on a specific diet nor a
        certain program of physical exercise Complaining of infertility either primary or secondary
        due to PCOS.

        N.B: The diagnosis of PCO syndrome was made according to the Androgen Excess and Polycystic
        Ovarian Syndrome Society: the presence of the following criteria have been required for the
        diagnosis of PCO syndrome:

        Hyperandrogenism: Hirsutism and/or Hyperandrogenaemia Ovarian Dysfunction :
        Oligo-Anovulation and /or Polycystic ovaries Exclusion of other Androgen Excess or related
        disorders as :( deficient nonclassic adrenal hyperplasia, androgen-secreting neoplasms,
        androgenic/anabolic drug use or abuse, Cushing's syndrome, the Hyperandrogenic-Insulin
        Resistance-Acanthosis Nigricans syndrome, thyroid dysfunction, and hyperprolactinemia).

        Exclusion Criteria:

          -  Age below 20 or above 40. Women who intended to start a diet or a specific program of
             physical activity. Concurrent medical illness as cardiovascular, neoplastic and
             hepatic disorder. Pelvic pathology. Tubal, Uterine, Male factor of infertility.
             Endocrinological factors including: diabetes Mellitus,hypothyroidism,
             hyperprolactinaemia, Cushing's syndrome, and non- classical congenital adrenal
             hyperplasia.

        Patients who are ovulatory during the ovarian cycle
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waleed Khalaf, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University Maternity Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>1156</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2018</study_first_submitted>
  <study_first_submitted_qc>April 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <last_update_submitted>April 1, 2018</last_update_submitted>
  <last_update_submitted_qc>April 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>Mohamed Adel mohamed kamal Eldin Abdelrahman</investigator_full_name>
    <investigator_title>Resident of Obstetrics and gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Anovulation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

